Scopolamine market

Q: Which is the leading dosage form segment in the market?

Patches is the leading dosage form segment in the market. Read more

Scopolamine Market, by Dosage Form (Tablet, Syrup, Injection, Patch, and Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jul 2022
CMI1965
151 Pages
Excel & Pdf
Pharmaceutical

Summary

Scopolamine, also known as hyoscine, or devil's breath, is a natural or synthetically produced tropane alkaloid and anticholinergic drug that is formally used as a medication for treating motion sickness and postoperative nausea and vomiting. Scopolamine is an oral, intravenous, ophthalmic or topical drug derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus Niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. It has applications in prevention of nausea, vomiting, and dizziness associated with motion sickness and recovery from anesthesia and surgery. Scopolamine may also be used to treat certain stomach or intestinal problems, such as spastic muscle states, diverticulitis, irritable bowel syndrome, Parkinson-like conditions etc.

Global Scopolamine market is estimated to be valued at US$ 462.7 million in 2022 and is expected to exhibit a CAGR of 4.8% during the forecast period (2022-2030).

Figure 1. Global Scopolamine Market Share (%), by Dosage Form, 2022

Increasing prevalence of motion sickness is expected to drive growth of the scopolamine market.

Increasing prevalence of motion sickness is expected to drive the global scopolamine market growth over the forecast period. For instance, according to an article published by Cureus, an open access general medical journal, in January 2021, a cross-section study was conducted in the internal medicine unit of a tertiary care hospital in multiple cities of Pakistan from June 2019 to August 2019, to find out the prevalence of irritable bowel syndrome in healthy population and determine the characteristics of symptoms. According to the results, the prevalence of Irritable Bowel Syndrome in general population was 33.2%.

Scopolamine Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 462.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	4.8%	2030 Value Projection:	US$ 675.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Dosage Form: Tablet, Syrup, Injection, Patch, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation
Growth Drivers:	Increasing prevalence of motion sickness Rise in research & development activities for developing neurotherapeutics
Restraints & Challenges:	Side effects and misuse of scopolamine

Figure 2.Global Scopolamine Market Share (%), by Region, 2022

Rise in research & development activities for developing neurotherapeutics is expected to drive the global scopolamine market growth.

Increasing research and development activities by the key players in market for the development of neurotherapeutics is expected to drive the global scopolamine market growth. For instance, in March 2022, Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing neurotherapeutics, used scopolamine a novel small molecule candidate for Alzheimer’s, Parkinson’s disease dementia and Dementia with Lewy bodies, and ATH-1020, an orally available, brain-penetrant small molecule candidate for neuropsychiatric conditions. The use of scopolamine is done in symptomatic treatment of Parkinson's disease.

Global Scopolamine Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global scopolamine market, owing to the decrease in the number of surgical interventions resulting from chronic diseases due to the ongoing Covid-19 pandemic. For instance, in May 2020, according to data published by National Center for Biotechnology Information, surgical practice has been significantly impacted with all special guidelines to manage crisis. The pandemic had ramifications for ways of working, surgical techniques, open vs. minimally invasive, theatre workflow, patient and staff safety, training and education. With guidelines specific to each specialty being implemented and followed, surgeons should be able to continue to provide safe and effective care to their patients during the COVID-19 pandemic. With the disruption of normal surgical practices due to workforce shortages as well as resource limitations due to COVID-19, it was important to rationalize all surgeries undertaken. Surgical teams were encouraged to offer telephone or video consultations when possible, cancel follow ups which were deemed non-essential in an attempt to minimize patient contact. Thus, the surgical procedures were reduced, which decreased the need of scopolamine transdermal patch as it was used to prevent nausea and vomiting after anesthesia, narcotic pain medicines, and surgery.

Global Scopolamine Market: Key Developments

On July 6 2022, Bayer HealthCare Pharmaceuticals Inc., Germany- Based pharmaceutical and life Sciences Company, launched its product Transderm-Scop (skin patch) in the retail as well as online platform market with revised formula of 1MG/72HR, which got approval from the U.S. Food and Drug Administration.

Moreover, in November 2020, Riconpharma LLC, a pharmaceutical company, got approval from the U.S. Food and Drug Administration to manufacture the generic version of Transderm-Scop (skin patch).

Global Scopolamine Market: Restraint

The major factors that hinder growth of the global scopolamine market include side effects and misuse of scopolamine. For instance, in January 2018, according to the data published in PubMed scopolamine drug is more common and easily available in Colombia, where it is used to make victims carry out sexual assaults and robberies. Furthermore, online availability of this drug at low cost is abused by sexual predators and robbers frequently in various European countries (in the U.K., scopolamine can be bought online for only US$ 12.8) might bring stringent regulations against the manufacturing and marketing of this drug in 2025 which may affected growth of the scopolamine market.

Key Players

Major players operating in the global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.

Table of Content

Table of Contents

*Browse 19 market data tables and 23 figures on "Global Scopolamine Market” - forecast to 2030

Segmentation

Detailed Segmentation:

Global Scopolamine Market, By Dosage Form:
- Tablet
- Syrup
- Injection
- Patch
- Others
Global Scopolamine Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Scopolamine Market, By Region:
- North America
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Dosage Form:
    - Tablet
    - Syrup
    - Injection
    - Patch
    - Others
  - By Distribution Channel:
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Region/Country
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global scopolamine market during the forecast period (2022-2030)?

The global scopolamine market size is estimated to be valued at US$ 462.7 million in 2022 and is expected to exhibit a CAGR of 4.8% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing prevalence of motion sickness and rise in research & development activities for developing neurotherapeutics are expected to drive the market growth.

Which is the leading dosage form segment in the market?

Patches is the leading dosage form segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include side effects and misuse of scopolamine.

hich are the major players operating in the market?

Major players operating in the market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.